Background
==========

Embryonic stem (ES) cells isolated from the inner cell mass of the early mammalian blastocyst-stage embryo retain pluripotency when cultured on mouse embryonic fibroblasts (MEFs) in the presence of leukemia inhibitory factor (LIF) \[[@B1]\]. In the absence of LIF and MEF attachment, ES cells spontaneously differentiate into multi-cellular aggregates termed embryoid bodies (EBs). Although the spatial complexity of organogenesis is not established during EB maturation, the dynamics of gene expression closely mimic those which characterize early stages of mouse development \[[@B2]-[@B5]\]. Thus, ES cell differentiation is an excellent model system for the discovery of genes involved in developmental processes.

Many studies have attempted to identify genes that define the stem cell state by mining for genes co-expressed in ES cells and various other stem cell populations such as hematopoietic and neural stem cells \[[@B6],[@B7]\], or ES cells and trophoblast stem cells \[[@B8]\]. Some of these studies have been criticized because they were unable to define a similar cohort of stem cell genes \[[@B9]\]. Also, this approach is likely to find co-expression of \'housekeeping\' genes that are irrelevant to the stem cell state. More recently, dynamic expression profiling during ES cell differentiation has been undertaken using various EB culture techniques \[[@B10],[@B11]\] and the addition of exogenous growth factors \[[@B7]\]. Most of these studies followed differentiation for a short time period (up to 6--8 days) due to inherent limitations of liquid or adherent cultures cell differentiation systems.

Various platforms have been used to determine gene expression profiles, including differential display, SAGE \[[@B12]\] and slide micro-arrays, such as those provided by Affymetrix, Agilent and Compugen. In this study we employed Illumina^®^Sentrix Mouse-6 oligo bead arrays \[[@B13]\], which have \~47 K probes that are largely based on the MEEBO set of transcripts, plus ESTs discovered as part of the FANTOM2 transcriptome project \[[@B14]\], some alternatively employed exons, and a small subset of non-coding transcripts. This is a new, rich and sensitive platform for expression profiling \[[@B15]\].

ES cells were differentiated in methylcellulose cultures, which allowed consistent EB development over 16 days in either serum \[[@B2],[@B16]\] or defined serum-free media containing BMP4 (2 ng/ml), termed serum-free^B4L^hereafter \[[@B17]\]. The dynamics of loss of stem cell gene expression and activation of epiblast and primitive streak gene expression programs were similar in serum and serum-free^B4L^but QT clustering revealed a significant difference in mesoderm outcomes from day 6 onwards. In particular, cardiac gene expression was greater in serum-free^B4L^whereas activation of the blood program was enhanced in serum.

High expression levels of Kruppel-like factor (KLF) family members: *Klf2*, *Klf4*, *Klf5*and *Klf9*was detected in undifferentiated ES cells, and confirmed by quantitative real time RT-PCR, indirect immuno-fluorescence and DNA-binding assays. Expression was down regulated rapidly upon differentiation and a different set of *Klfs: Klf3*, *Klf16*and *Klf1/Eklf*, were activated upon ES cell differentiation. Also, KLF-binding sites were markedly over represented in the proximal promoters of most stem cell specific genes, suggesting possible direct regulation by KLFs. We suggest a model in which the balance between self-renewal and differentiation is regulated by competitive occupancy of the proximal promoters of key stem cell genes such as *Zfp42/Rex-1*, *Nanog*, *Pou5f1(Oct4)*, *Lefty1*and *Lefty2*, and others such as the *Klf*genes themselves.

Results
=======

Differentiation of ES cells in serum and serum-free^B4L^culture
---------------------------------------------------------------

The directed differentiation of embryonic stem cells into desirable cell types will depend upon the addition of specific growth factors to defined media and reproducible physical conditions of culture. To establish a baseline for such studies, we undertook a comparison of murine ES cell differentiation using an embryoid body (EB) methylcellulose culture system containing either 10% FBS \[[@B2]\] or a chemically defined BSA-based media containing 2 ng/ml of BMP4, termed serum-free^B4L^\[[@B17]\]. Triplicate experiments were performed in which ES cells were harvested after feeder depletion, and set up in parallel EB cultures in serum versus serum-free^B4L^. RNA was collected at regular intervals up to 16 days, quantitative RT-PCR was performed on a panel of genes representing defined stages of development to establish the robustness of the culture system (Figure [1](#F1){ref-type="fig"}), and expression profiling was performed using Illumina^®^Sentrix Mouse-6 bead arrays (see Methods and \[[@B13]\]).

![**Dynamic gene expression during EB differentiation in serum and serum-free media containing BMP4 \[2 ng/ml\]**. Expression of stem cell, primitive streak and late mesoderm genes were analysed by quantitative RT-PCR in undifferentiated ES cells (0, grey bar) and in EBs collected for up to 16 days in serum (white bars) or defined media (black bars) from the same starting ES cell populations. Bars represent the means of three (serum) or two (serum-free^B4L^) biological replicates. The Y-axis represents a log scale normalized relative to the housekeeping gene HPRT. Error bars indicate standard deviation.](1471-2164-8-365-1){#F1}

Changes in gene expression were extremely reproducible across ES differentiation experiments with overall correlation of global gene expression for biological replicates in the order or 0.95--0.96. Approximately 30% of the probes were differentially expressed at one or more stages of EB differentiation as determined by one-way Welch ANOVA with multiple testing corrections using the Benjamini and Hochberg False Discovery Rate algorithm (7,967 probes with a p-value of \< 0.01 by Welch t-test) (Figure [2A](#F2){ref-type="fig"}).

![**Gene expression profiles during 16 days of EB differentiation in serum and serum-free media containing BMP4 \[2 ng/ml\]**. (**A**) GeneSpring representation of the subset of genes from the 48 K Illumina array that showed significant differences in gene expression at 2 or more time points. Each line represents the mean normalised expression of an individual Illumina probe. Colours represent relative expression (red 4× increased; green 0.25× reduced) compared to a gene mean of 1 (black) with expression in undifferentiated ES cells (day 0) as the decision point for colour coding. The expression profiles of T (brachyury), Hba (α-globin), and Igf2 are indicated for reference. (**B**) Clustering (tree) of the genes that showed significant (p \< 0.01) changes in gene expression upon differentiation by One-way Welch ANOVA. Expression levels are heat map colour coded (inset) with high expression at Day 0 coloured red and low expression coloured green.](1471-2164-8-365-2){#F2}

To mine for genes with similar patterns of expression across the time course, hierarchical clustering was performed on the 7,967 probes and represented graphically. A large percentage of these (\~30%) displayed highest expression in undifferentiated ES cells and subsequent reduced expression over time (labeled **stem**in Figure [2B](#F2){ref-type="fig"}). A second major cluster showed marked induction after \~day 4--6 of differentiation (labeled **mesoderm**in Figure [2B](#F2){ref-type="fig"}).

Putative stem cell genes sets
-----------------------------

Previous studies have identified genes important to the stem cell state by comparing expression profiling data from different stem cell populations such as ES cells, haematopoietic stem cells (HSCs) and neural stem cells \[[@B6],[@B18]\]. We used two alternative approaches to identify specific stem cell specific gene expression. Firstly, genes with dynamic expression patterns which correlated closely with *Oct4*, *Sox2*or *Nanog*expression profiles (Pearson correlation \> 0.9) were determined as previously described \[[@B6],[@B7]\]. Second, genes rapidly down regulated ≥3 fold by day 3 of differentiation, a time point where ES cell clonogenicity decreases dramatically, were determined. Not surprisingly there was very little overlap between these gene lists, primarily because *Oct4*and *Nanog*expression persists during EB differentiation longer than many other stem cell genes (Figure [1](#F1){ref-type="fig"}). Full lists of genes ranked according to similarity of expression (Pearson correlation \>0.9) with expression patterns for *Oct4*, *Nanog*or *Sox2*are provided in Additional files [1](#S1){ref-type="supplementary-material"}, [2](#S2){ref-type="supplementary-material"}, [3](#S3){ref-type="supplementary-material"}, respectively.

Only fifty-nine genes were down regulated ≥3 fold by day 3 of EB differentiation (Table [1](#T1){ref-type="table"}). Many of these have been identified as stem cell markers by other groups using alternative strategies \[[@B6],[@B7],[@B19]\]. Information was compiled on their known expression patterns and/or gene knockout phenotypes via literature searches as referenced in Table [1](#T1){ref-type="table"}. Insufficient space exists to discuss every gene and most have been previously identified as ES cell enriched transcripts. Osteopontin is secreted by osteoblasts in the bone marrow niche where it is thought to play an important role in the maintenance of HSC quiescence and maintenance of \'stemness\' \[[@B20]\]. It has also been discovered by other groups as a strong marker of ES cells and is regulated directly by the key stem cell transcription factors, Oct4 and Sox2 \[[@B21]\]. Thus, osteopontin is likely to be a useful marker of ES cell pluripotency and may play autocrine or paracrine roles in maintenance of stemness. The second most rapidly down regulated gene was estrogen related receptor β, *Esrrb*, which had previously been identified as a stem cell specific gene and shown to be critical for maintenance of the stem cell state \[[@B19]\]. F-box 15 (*Fbxo15*), a member of the large F-box family of genes \[[@B22]\] was also rapidly down regulated. *Fbxo15*is known to be highly expressed in ES cells, is regulated by Oct4 and Sox2, but is dispensable for ES cell self-renewal \[[@B23]\]. Recently, the stem cell specificity of this locus was used to screen for cDNAs capable of transforming mouse fibroblasts into ES cell populations \[[@B24]\]. Other notable rapidly down regulated genes included the nodal inhibitors *Lefty-1*and *Lefty-2*, and *Zfp42*/*Rex-1*, which are also well established as stem cell markers \[[@B19]\].

###### 

Genes rapidly down regulated (\>3 fold in 3 days) upon ES cell differentiation

  **Gene Name**                                   **Synonyms**                   **Genbank ID**                     **Fold ↓ D0 → D3**   **Raw D0**   **Function**                           **Refs**
  ----------------------------------------------- ------------------------------ ---------------------------------- -------------------- ------------ -------------------------------------- -------------
  Secreted phosphoprotein 1                       Osteopontin; Spp1              [NM_009263](NM_009263)             26.8                 3588         Reg. by Oct4 and Sox2                  \[21, 96\]
  Estrogen related receptor, beta                 Err2; Estrrb; Nr3b2            [NM_011934](NM_011934)             24.0                 4238         ES cell renewal, placenta              \[97\]
  F-box 15                                        Fbx15                          [NM_015798](NM_015798)             21.8                 4487         Stem cell specific locus               \[23\]
  RIKEN cDNA 2200001I15                           2200001I15Rik                  [NM_183278](NM_183278)             18.3                 2780                                                
  **Kruppel-like factor 2**                       **Klf2; Lklf**                 [NM_008452](NM_008452)             17.0                 2639         Vascular defect                        \[49\]
  Left-right determination, factor B              Leftb; Stra3; Tgfb4; Lefty 1   [NM_010094](NM_010094)             14.4                 2537         Nodal signalling inhibitor             \[87\]
  Transcription factor CP2-like 1                 Crtr-1; LBP-9                  [NM_023755](NM_023755)             13.8                 2237         ES cells, repressor                    \[98\]
  Zinc finger protein 42                          Rex-1; Rex1; Zfp-42            [NM_009556](NM_009556)             13.4                 2108         Nanog-Sox2 induced                     \[99, 100\]
  L-threonine dehydrogenase                       Tdh                            [NM_021480](NM_021480)             10.9                 1764         L-threonine degradation                \[101\]
  DNA (cytosine-5-)-methyltransferase 3-like      D6Ertd14e, Dnmt3l              [NM_019448](NM_019448)             10.8                 5226         Maternal imprinting                    \[102\]
  Transcription elongation factor A, 3            S-II, Tcea3                    [NM_011542](NM_011542)             8.6                  3874         ICM Expression                         \[103\]
  Myosin light chain, skeletal muscle             MLC-2; Mlc2, Mylpf             [NM_016754](NM_016754)             8.6                  1560         Cardiac muscle                         \[104\]
  S100 calcium binding protein A6                 Cacy, S100a6, calcyclin        [NM_011313](NM_011313)             8.2                  9086         Cell cycle regulation                  \[105\]
  Testis expressed gene 19                        Tex19, 2410081M02Rik           [NM_028602](NM_028602)             8.1                  1963         Spermatogonia                          \[106\]
  Epithelial membrane protein 1                   TMP, Emp1                      [NM_010128](NM_010128)             7.9                  1030         Neuronal differentiation               \[107\]
  DNA segment, Chr 11, ERATO Doi 636              D11Ertd636e                    [NM_029794](NM_029794)             7.9                  1278         Expressed in Morula                    \[108\]
  Similar to solute carrier family 7, member 3    Slc7a3                         [. NM_001004153](. NM_001004153)   7.3                  1036                                                
  Left-right determination, factor 2              Lefta; Ebaf; Lefty 2           [NM_177099](NM_177099)             7.2                  1903         Inhibitor of Nodal                     \[109\]
  Junction adhesion molecule 2                    Jcam2; VE-JAM, Jam2            [NM_023844](NM_023844)             6.5                  713          KO normal                              \[110\]
  Lysosomal-associated protein, transmembrane 5   E3, Laptm5                     [NM_010686](NM_010686)             6.5                  1539         haematopoiesis                         \[111\]
  Discoidin domain receptor 1                     Drr1, MCK10, EDDR1             [. NM_007584](. NM_007584)         6.4                  5451         Collagen response receptor             \[112\]
  Aminoadipate-semialdehyde synthase              Aass, LKR/SDH; Lorsdh          [NM_013930](NM_013930)             6.2                  1094         Mitochondria                           \[113\]
  RIKEN cDNA 2410039E07                           2410039E07Rik                  [NM_212483](NM_212483)             6.2                  737                                                 
  RIKEN cDNA 2410004A20                           2410004A20Rik                  [NM_025890](NM_025890)             5.7                  644                                                 
  Gastrulation brain homeobox 2                   Gbx2, MMoxA;Stra7              [NM_010262](NM_010262)             5.6                  1204         Midbrain/hindbrain organiser           \[114\]
  cDNA sequence BC050188                          4933403D14                     [NM_177742](NM_177742)             5.6                  497                                                 
  Cordon-bleu                                     Cobl, C530045F18Rik            [NM_172496](NM_172496)             5.1                  619                                                 
  Similar to EF 1A                                eIF-1A, eIF-4C                 [XM_181357](XM_181357)             5.0                  538                                                 
  Regulatory factor X, 2                          Rfx2                           [NM_009056](NM_009056)             4.9                  796          ICM expression                         \[103\]
  Tissue inhibitor of metalloproteinase 1         Clgi;Timp;TIMP-1               [NM_011593](NM_011593)             4.6                  1732         Metalloproteinase inhibitor matrix     \[115\]
  **Kruppel-like factor 4**                       **Klf4, Gklf;**Zie             [NM_010637](NM_010637)             4.5                  597          Epidermal, gut defect                  \[116\]
  Insulin-like growth factor binding protein 7    Igfbp7, Fstl2, mac25           [NM_008048](NM_008048)             4.4                  813                                                 
  latent transforming growth factor BP4           Ltbp4, 2310046A13Rik           [NM_175641](NM_175641)             4.4                  481                                                 
  DnaJ (Hsp40) homolog, subfamily C, 6            Dnajc6, 2810027M23Rik          [NM_198412](NM_198412)             4.3                  490                                                 
  **Kruppel-like factor 5**                       **Klf5**, Bteb2, IKLF          [NM_009769](NM_009769)             4.3                  1797         Cardiovascular remodelling             \[117\]
  Nuclear receptor subfamily 5, group A, 2        Nr5a2, Ftf;LRH-1               [NM_030676](NM_030676)             4.2                  494          Ovary granulosa cells                  \[118\]
  RIKEN cDNA D230005D02                           B230207J08                     [NM_172813](NM_172813)             4.2                  433                                                 
  Nuclear protein 1                               Nupr1, Com1;p8                 [NM_019738](NM_019738)             4.1                  388          KO normal                              \[119\]
  Intercellular adhesion molecule                 Icam1, CD54, Icam-1            [NM_010493](NM_010493)             4.1                  716          KO normal, inflammation                \[120\]
  Interleukin-1 receptor-associated kinase 3      Irak3, IRAK-M                  [NM_028679](NM_028679)             3.9                  409          Immune homeostasis                     \[121\]
  Keratin complex 1, acidic, gene 17              Krt1-17, K17                   [NM_010663](NM_010663)             3.9                  368          Embryonic ectoderm                     \[122\]
  Stathmin-like 2                                 Stmn2, Scgn10, Stmb2           [NM_025285](NM_025285)             3.9                  712          KO normal, cell cycle                  \[123\]
  Suppressor of cytokine signaling 3              Socs3, CIS3, SSI-3             [NM_007707](NM_007707)             3.8                  1081         LIF singalling                         \[124\]
  Lipase, member H                                Lpdlr; PLA1B Liph              [NM_153404](NM_153404)             3.8                  446          Lipid metabolism                       \[125\]
  RIKEN cDNA 4933405K07                           4930427I11Rik                  [NM_028913](NM_028913)             3.8                  573                                                 
  Erythrocyte protein band 4.1-like 4a            Epb4.1l4, NBL4                 [NM_013512](NM_013512)             3.8                  809          beta-catenin/Tcf pathway               \[126\]
  Polo-like kinase 3 (Drosophila) (Plk3)          Cnk, Fnk, PRK                  [NM_013807](NM_013807)             3.7                  567          Mitosis regulator                      \[127\]
  Heat shock protein 1 (Hspb1)                    27 kDa, Hsp25                  [NM_013560](NM_013560)             3.7                  3731         Blastocyst expression                  \[128\]
  RIKEN cDNA 1700061G19                           1700061G19Rik                  [XM_140052](XM_140052)             3.7                  425                                                 
  Mannosidase, beta A, lysosomal                  Bmn, Manba                     [NM_027288](NM_027288)             3.7                  484          Glycoprotein cleavage, KO normal       \[129\]
  Developmental pluripotency-associated 3         PCG7, Stella, Dppa3            [NM_139218](NM_139218)             3.6                  450          Expressed in preimplantation embryos   \[130\]
  Lysyl oxidase                                   TSC-160, Lox                   [NM_010728](NM_010728)             3.6                  644          KO cardiovascular defects              \[131\]
  RIKEN cDNA E130014J05                           Tet2                           [NM_145989](NM_145989)             3.5                  866                                                 
  Myeloblastosis oncogene-like 2                  B-myb, Mybl2                   [NM_008652](NM_008652)             3.3                  718          Cell proliferation G1/S transition     \[132\]
  Pleckstrin homology domain containing, A4       PEPP1, Plekha4                 [NM_148927](NM_148927)             3.3                  532          Preimplantation embryo expression      \[108\]
  Aurora kinase C (Aurkc)                         AIK3, Stk13                    [NM_020572](NM_020572)             3.3                  305          Chromosome segregation                 \[133\]
  Fibroblast growth factor binding protein 1      FGF-BP, Fgfbp1                 [NM_008009](NM_008009)             3.1                  312          Enhances FGF activity                  \[134\]
  Caveolin, caveolae protein 1                    Cav1                           [NM_007616](NM_007616)             3.1                  438          KO viable, vascular defects            \[135\]

*Oct4*, *Nanog*and *Sox2*are not included in Table [1](#T1){ref-type="table"}, even though each is required for the maintenance of ES cell pluripotency \[[@B25]-[@B27]\] due to their persistent expression during the first 3 days of EB differentiation (Figure [1](#F1){ref-type="fig"} and [5A](#F5){ref-type="fig"}, and Additional file [1](#S1){ref-type="supplementary-material"}). Indeed, *Oct4*expression is known to persist beyond the inner cell mass stage of development *in vivo*, with transcripts detected in the epiblast and later in the primitive streak, before it becomes further restricted to primordial germ cells \[[@B10],[@B28]\]. 779 genes with a similar pattern of expression to *Oct4*(Pearson correlation of \> 0.9) were identified (Additional file [1](#S1){ref-type="supplementary-material"}). As expected this list also includes many well known stem cell genes such as Sal-like 1, *nodal*, chromobox homolog 7 (*Cbx7*), *Dnmt3b*and Sprouty homolog 4 \[[@B19]\]. We also mined for stem cell genes by looking for similarity (Pearson correlation of \> 0.9) with *Nanog*and *Sox2*gene expression profiles. These provided overlapping but not identical sets of putative stem cell specific genes (Additional files [2](#S2){ref-type="supplementary-material"}, [3](#S3){ref-type="supplementary-material"}). Full data for the 16 days of differentiation can be interrogated and mined for specific differentiation outcomes via Signet (Login_Bruce) (see Methods).

Tightly co-ordinated waves of gene expression suggest sequential activation of epiblast, primitive streak and mesoderm differentiation programs
-----------------------------------------------------------------------------------------------------------------------------------------------

Many alternative differentiation programs occur simultaneously during ES cell differentiation. Therefore, it is difficult to find gene syn-expression patterns that identify specific programs using standard clustering methods. An alternative approach is to search for expression patterns that closely resemble genes of known function. For example, the T box gene, brachyury, is a well characterized specific marker of the primitive streak \[[@B29]\]. Brachyury expression is transient *in vivo*, a feature recapitulated during ES cell differentiation \[[@B2]\]. Using qRT-PCR, brachyury was induced \~1000 fold from D0 to day 4 and then rapidly silenced to baseline levels by D6 (Figure [1](#F1){ref-type="fig"}). The dynamics of brachyury expression were similar between serum and serum-free^B4L^media (Figure [1](#F1){ref-type="fig"} and [3A](#F3){ref-type="fig"}), but serum-free media was unable to support brachyury induction in the absence of BMP-4 (data not shown). Thus, BMP4 (or related factors in serum such as activin) is essential for mesoderm generation. Thirty genes were identified with a similar expression pattern to brachyury (Pearson correlation \>0.9) (Table [2](#T2){ref-type="table"}) including many genes with established expression or critical functions during primitive streak formation, such as *Mix1*\[[@B30]\], *Lim1*\[[@B31]\], *Sp5*\[[@B32]\] and *eomesodermin*\[[@B33]\]. Transient expression of many of these \'streak-specific\' genes was validated by qRT-PCR (Figure [3B](#F3){ref-type="fig"} and data not shown). In all cases there was a close correlation between the qRT-PCR results and the profiling data (Figure [3A](#F3){ref-type="fig"}).

![**Mining for genes expressed in patterns consistent with primitive streak, and epiblast differentiation programs**. (**A**) GeneSpring representation of epiblast and streak gene expression profiles during EB differentiation in 10% serum or serum-free^B4L^culture. The up-regulation of genes between days 2--4 were similar under both conditions. (**B**) qRT-PCR analysis of Mixl, Lim1, Cdx4 and Riken clone 8430415E04Rik. The Y-axis represents expression relative to the housekeeping gene HPRT. Error bars indicate ± SD from three biological replicates. (**C**) 102 genes transiently up regulated during the first 4 days of ES cell differentiation were clustered using a tree algorithm and Pearson correlation of \> 0.9. The \'**Brief**\' group represents gene with very transient expression at day 3. (**D**) Coding region for 8430415E04Rik. The shaded areas represent the three Heat domains.](1471-2164-8-365-3){#F3}

###### 

Brachyury-like (Primitive Streak) gene list (Pearson correlation \>0.9 with brachyury)

  **Description**                                 **Symbol**      **Corr**.   **Synonyms**           **Genbank ID**               **Expression/Function**
  ----------------------------------------------- --------------- ----------- ---------------------- ---------------------------- ------------------------------------------
  Brachyury (T)                                   T               1.00        cou;Low;Lr;;T1         [NM_009309.1](NM_009309.1)   \[33, 136\] Primitive streak
  Eomesodermin \*                                 Eomes           0.98        Tbr2                   [NM_010136.1](NM_010136.1)   \[33\] Primitive streak
  Fibroblast growth factor 8                      Fgf8            0.97        Aigf;Fgf-8             [NM_010205.1](NM_010205.1)   \[137\] primitive streak expression
  Mix1                                            Mixl1           0.97        Mm1;Mml                [NM_013729.2](NM_013729.2)   \[30\] KO primitive streak abnormal
  Lysophospholipase isoform 1                     A530050D06Rik   0.97                               [XM_203596](XM_203596)       
  LIM homeobox protein 1 \*                       Lhx1            0.96        Lim1; Lhx1             [NM_008498](NM_008498)       \[31\] Primitive streak expression
  Mesoderm posterior 1                            Mesp1           0.95                               [NM_008588.1](NM_008588.1)   \[138\] nascent mesodermal cells
  Sp5                                             Sp5             0.94                               [NM_022435.2](NM_022435.2)   \[32\] Primitive streak expression
  8430415E04Rik \*                                8430415E04Rik   0.94        unknown                [NM_028980.1](NM_028980.1)   
  Axin2                                           Axin2           0.94        Axi1;Axil;Conductin    [NM_015732.3](NM_015732.3)   \[139\] Wnt signalling inhibitor
  Ninein                                          Nin             0.93        mKIAA1565              [NM_008697](NM_008697)       \[140\] Centrosome anchoring
  E330009J07Rik                                   E330009J07Rik   0.93        mKIAA1147              [NM_175528](NM_175528)       
  Proteosome subunit, beta 8 \*                   Psmb8           0.93        Lmp-7;Lmp7             [NM_010724.1](NM_010724.1)   \[141\] reduced MHC class I
  Solute carrier family 30 member 3               Slc30a3         0.93        Znt3                   [NM_011773](NM_011773)       \[142\] KO no phenotype
  DHHC-type Zn-finger containing protein          2400007G07Rik   0.92                               [AK010296](AK010296)         
  Chemokine (C-C motif) ligand 20                 Ccl20           0.92                               [NM_016960](NM_016960)       \[143\] T and B cell regulation
  Protease 28 subunit, beta \*                    Psme2b          0.92        PA28b-p;Psme2-like     [NM_011191.1](NM_011191.1)   \[144\] MHC Class I regulation
  D130029J02Rik                                   D130029J02Rik   0.92                               [XM_150103](XM_150103)       
  F-box and leucine-rich repeat protein 14        Fbxl14          0.92        Fbx14l                 [NM_133940](NM_133940)       
  WD repeat & FYVE domain containing 1            Wdfy1           0.92        FENS-1;Jr1;WDF1        [NM_027057](NM_027057)       \[145\] Endosome and Golgi regulation
  ADP-ribosylation factor-like 6 int. protein 2   Arl6ip2         0.92        Aip-2;AV334690         [NM_019717.1](NM_019717.1)   
  Protease 28 subunit, alpha                      Psme1           0.92        PA28a                  [NM_011189.1](NM_011189.1)   \[146\] Proteasome activator MHC Class I
  TAF10                                           Taf10           0.92        30 kDa;Taf2h;TAFII30   [NM_020024.3](NM_020024.3)   \[147\] KO ICM phenotype
  Helicase with zinc finger domain                Helz            0.91                               [NM_198298](NM_198298)       \[148\] Primitive streak expression
  Transmembrane 4 superfamily member 10           Tm4sf10         0.91        BCMP1                  [NM_175771.2](NM_175771.2)   
  1190004M23Rik                                   1190004M23Rik   0.90                                                            
  Carbonic anhydrase 14                           Car14           0.90                               [NM_011797.1](NM_011797.1)   \[149\] KO no phenotype
  Male enhanced antigen 1                         Mea1            0.90        Mea-1                  [NM_010787.1](NM_010787.1)   \[150\] Testis development
  Delta-like 3, transcript variant 1              Dll3            0.90        pu;pudgy               [NM_007866.1](NM_007866.1)   \[151\] primitive streak expression
  Ring finger protein 30                          Rnf30           0.90        MURF;MURF-3            [NM_021447.1](NM_021447.1)   \[152\] Myogenic regulator

\* More than one independent illumina probe for these genes were identified

Interestingly, four novel transcripts were identified in this list (Table [2](#T2){ref-type="table"}). One of these, 8430415E04Rik, was detected by two independent probes, strongly supporting its \'streak-specific\' expression; by qRT-PCR there was \~50 fold induction from day 2 to day 3 of differentiation and a decrease to near baseline levels by day 6 (Figure [3B](#F3){ref-type="fig"}). The gene contains 24 exons, and the full length cDNA encodes for a protein of 868 amino acids (Figure [3D](#F3){ref-type="fig"}) which is highly conserved in vertebrates (Additional file [4](#S4){ref-type="supplementary-material"}). It has little homology to other proteins apart from three predicted HEAT domains or *armadillo*domains (grey shading in Figure [3D](#F3){ref-type="fig"}). Drosophila *armadillo*interacts with β-catenin via its HEAT/armadillo repeat \[[@B34]\], which suggests the protein encoded by 8430415E04Rik may also be involved in protein-protein interactions.

The list of primitive streak genes in table [2](#T2){ref-type="table"} is smaller than that previously published \[[@B10]\] due to the very stringent criteria used to determine brachyury-like patterns of expression. Thus, to find further genes characteristic of epiblast, early and late primitive streak programs, probes were identified which were transiently up and down regulated at least two fold with peak expression at day 2, 3 or 4 of EB differentiation. Gene lists were combined (102 Illumina probes) and clustered into epiblast, early, mid and late streak groups plus a unique group in which expression was very transient at day 3 of differentiation (designated \'brief\' at the bottom of Figure [3C](#F3){ref-type="fig"}). Also, lists were generated by searching for similarity of dynamic expression profiles to known genes which are accepted specific markers of specific stages of mouse development. For example, *Fgf5*is specifically expressed in the epiblast \[[@B35]\], and *Wnt5a*is expressed in the late primitive streak \[[@B36]\]. The *Fgf5*-like (epiblast) list includes the methyltransferase, *Dnmt3b*, which was massively up-regulated in the first 2 days of EB differentiation (Additional file [5](#S5){ref-type="supplementary-material"}) and is known to be essential for mesoderm differentiation \[[@B37]\]. This list also includes *Pim2*, *Zic2*, *Wnt8a*, the SP1 (and possibly SP5) cofactor *Crsp2*, and *Irf1*. The W*nt5a*-like (late primitive streak) list contains 76 genes including many homeobox genes (*Hoxb2*, *Hoxd1*, *Hoxb6*and *Hox8*/*Msx2*), *Cdx2*, *Hand1*, *Tbx3, Bmp4*and the VEGF receptor *Flt1*(Additional file [6](#S6){ref-type="supplementary-material"}). Many are expressed at E10 of mouse development in the remnants of the primitive streak \[[@B36]\], suggesting the *Wnt5a*-like list includes many genes known to pattern the embryo following formation of the germ layers. There is a significant overlap between the genes we identified as being epiblast-, early and late streak-specific and those recently identified using a similar EB differentiation system and Affymetrix arrays \[[@B10]\], and by other groups \[[@B2],[@B38]\]. In addition, there are addition novel RIKEN cDNAs in these lists, which are likely to encode for interesting proteins worthy of further study (Additional files [5](#S5){ref-type="supplementary-material"}, [6](#S6){ref-type="supplementary-material"}).

Following the primitive streak wave of gene expression there was a dramatic activation of many genes (Figure [2A](#F2){ref-type="fig"}). Many of the most highly induced genes, such as globin genes, heme synthesis enzymes and haematopoietic transcription factors, are known to be expressed in the blood. qRT-PCR for globin genes confirmed \> 10,000 fold induction between days 3 and 8 with a steady decline thereafter (Figure [1](#F1){ref-type="fig"}). Other mesoderm and endoderm programs are also activated at this stage, so it is difficult to mine for these different outcomes.

Enhanced cardiac gene expression and reduced erythropoiesis in serum-free^B4L^EB culture
----------------------------------------------------------------------------------------

Overall there were very strong similarities between ES cell differentiation in serum and serum-free cultures supplemented with 2 ng/ml BMP4. For example, all 29 of the primitive streak gene set, as defined from serum-containing cultures, were also expressed transiently and to a similar level in serum-free^B4L^media (Figure [3A](#F3){ref-type="fig"}). Genes differentially expressed at each EB time point (Day 1--16) were pooled and subjected to QT clustering to find sets differentially expressed between serum and serum-free^B4L^EB culture. Using a minimal cut-off of five genes per group, nine gene sets were identified; seven showed higher expression in serum and two showed higher expression in serum-free^B4L^(Table [3](#T3){ref-type="table"} and Figure [4](#F4){ref-type="fig"}).

###### 

Genes differentially expressed during ES cell differentiation in serum versus serum-free defined media (BMP4 2 ng/ml)

  **Set 1 -- Chemokine ligands (Day 8)**                                                Symbol        **Synonyms**                     **Genbank ID**               **BMP4**   **Serum**
  ------------------------------------------------------------------------------------- ------------- -------------------------------- ---------------------------- ---------- -----------
  Hydroxyprostaglandin dehydrogenase 15                                                 Hpgd                                           [NM_008278.1](NM_008278.1)   2.22       4.4
  Src-like adaptor                                                                      Sla           Slap                             [NM_009192](NM_009192)       1.29       .90
  Pleckstrin                                                                            Plek                                           [NM_019549.1](NM_019549.1)   1.31       4.9
  Triggering receptor expressed on myeloid cells-like 1                                 Treml1                                         [XM_128641.3](XM_128641.3)   1.67       12.6
  Glycoprotein 5 (platelet)                                                             Gp5           GPV                              [NM_008148.2](NM_008148.2)   1.52       8.9
  2810484G07Rik                                                                                                                                                     2.07       13.5
  Chemokine (C-X-C motif) ligand 7                                                      Cxcl7         b-TG1; CTAP3; LDGF; MDGF;NAP-2   [NM_023785.1](NM_023785.1)   1.07       4.8
  Angiotensin receptor 1                                                                Agtr1         AT1;AT1a;AT2R1                   [NM_177322.2](NM_177322.2)   1.58       5.8
  Arachidonate 12-lipoxygenase                                                          Alox12        Alox12p;P-12LO                   [NM_007440.2](NM_007440.2)   1.29       9.2
  Chemokine (C-C motif) ligand 4                                                        Ccl4          Act-2; MIP-1B                    [NM_013652](NM_013652)       1.81       19.5
  Chemokine (C-X-C motif) ligand 4                                                      Cxcl4         Pf4;Scyb4                        [NM_019932.1](NM_019932.1)   3.85       29.0
  ATPase, Ca^2+^transporting, ubiquitous                                                Atp2a3        Serca3                           [NM_016745.2](NM_016745.2)   1.30       6.1
  Chemokine (C-C motif) ligand 3                                                        Ccl3          Mip1a;Scya3                      [NM_011337.1](NM_011337.1)   1.75       11.8
                                                                                                                                                                               
  **Set 2 -- Globins (Day 6)**                                                          **Symbol**    **Synonyms**                     **Genbank ID**               **BMP4**   **Serum**
                                                                                                                                                                               
  β-major globin                                                                        Hbb-b1                                         [AK002258](AK002258)         2.15       21.7
  ζ-globin                                                                              Hba-x                                          [NM_010405.2](NM_010405.2)   4.30       128.3
  ε-y globin                                                                            Hbb-y         E-y                              [NM_008221.2](NM_008221.2)   1.80       38.1
  Nuclear factor erythroid-2 (p45)                                                      Nfe2          p45NFE2                          [NM_008685.2](NM_008685.2)   1.32       10.4
  α-globin                                                                              Hba-a1        Hba1                             [NM_008218.1](NM_008218.1)   3.21       89.7
  Band-3/anion exchanger 1                                                              Slc4a1        Ae1;CD233;Band 3                 [NM_011403.1](NM_011403.1)   1.19       26.2
  Rik2510042H12                                                                                                                        [AK011092](AK011092)         1.01       4.1
  Aminolevulinic acid synthase 2                                                        Alas2         Alas-2                           [NM_009653.1](NM_009653.1)   1.14       13.2
  β h1-globin                                                                           Hbb-bh1       betaH1                           [NM_008219.2](NM_008219.2)   3.65       61.2
                                                                                                                                                                               
  **Set 3 -- Blood (Day 8)**                                                            **Symbol**    **Synonyms**                     **Genbank ID**               **BMP4**   **Serum**
                                                                                                                                                                               
  Alpha hemoglobin stabilising protein                                                  AHSP          AHSP;EDRF                        [NM_133245.1](NM_133245.1)   1.7        3.4
  Myeloperoxidase                                                                       Mpo                                            [NM_010824](NM_010824)       1.1        3.6
                                                                                        Slc38a5       SN2; JM24                        [NM_172479.1](NM_172479.1)   1.3        2.5
  Glycophorin A                                                                         Gypa          CD235a;GPA                       [NM_010369.2](NM_010369.2)   2.1        5.2
  Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4     Cited4        Mrg2                             [NM_019563](NM_019563)       1.3        2.5
  Mitoferrin                                                                            Mscp          Slc25a37                         [NM_030054.2](NM_030054.2)   1.5        2.4
  Kruppel-like factor 1                                                                 Klf1          Eklf                             [NM_010635](NM_010635)       1.8        3.6
                                                                                                                                                                               
  **Set 4 -- Various (Day 16)**                                                         **Symbol**    **Synonyms**                     **Genbank ID**               **BMP4**   **Serum**
                                                                                                                                                                               
  FXYD domain-containing ion transport regulator 2                                      Fxyd2         Atp1g1                           [NM_007503](NM_007503)       1.38       6.7
  Thioether S-methyltransferase                                                         Temt                                           [NM_009349](NM_009349)       0.97       6.0
  Mus musculus FXYD domain-containing ion transport regulator 2, transcript variant a   Fxyd2         Atp1g1                           [NM_052824.1](NM_052824.1)   1.16       5.7
  Fibrinogen, alpha                                                                     Fga           Fib                              [NM_010196.1](NM_010196.1)   2.06       11.8
  Kininogen-1                                                                           Kng1                                           [NM_023125.2](NM_023125.2)   6.25       37.3
  Serum amyloid A 3                                                                     Saa3          Saa-3                            [NM_011315](NM_011315)       1.04       4.5
  Deleted in azoospermia-like                                                           Dazl          Dazla;Tpx-2;Tpx2                 [NM_010021.2](NM_010021.2)   0.91       3.8
  Fibrinogen, alpha                                                                     Fga           Fib                              [NM_010196.1](NM_010196.1)   2.57       14.3
  Chitinase 3-like 1                                                                    Chi3l1        brp-39;Brp39;Gp39                [NM_007695.1](NM_007695.1)   1.75       7.3
  Kininogen II                                                                                                                         [NM_201375.1](NM_201375.1)   1.73       7.9
                                                                                                                                                                               
  **Set 5 -- Macrophage (Day 16)**                                                      **Symbol**    **Synonyms**                     **Genbank ID**               **BMP4**   **Serum**
                                                                                                                                                                               
  Neutrophil cytosolic factor 2                                                         Ncf2          Ncf-2; p67phox                   [NM_010877](NM_010877)       2.05       3.56
  Complement component 1q beta                                                          C1qb                                           [NM_009777.1](NM_009777.1)   1.13       4.63
  Matrix metalloproteinase 12                                                           Mmp12         Mmel                             [NM_008605.1](NM_008605.1)   3.17       8.53
  Complement component 3                                                                C3            ASP;Plp                          [NM_009778.1](NM_009778.1)   2.17       10.46
  CD68 antigen                                                                          Cd68          gp110;Scard1                     [NM_009853](NM_009853)       1.84       5.58
  Macrophage expressed gene 1                                                           Mpeg1                                          [XM_129176](XM_129176)       3.08       6.74
  TYRO protein tyrosine kinase binding protein                                          Tyrobp        DAP12;KARAP;Ly83                 [NM_011662.2](NM_011662.2)   2.80       4.81
  Myosin IF                                                                             Myo1f                                          [NM_053214.1](NM_053214.1)   1.64       3.33
  Hematopoietic protein 1                                                               Hemp1                                          [NM_153505.2](NM_153505.2)   1.41       4.22
  Glutathione S-transferase, alpha 3                                                    Gsta3         Gst2-3                           [NM_010356.2](NM_010356.2)   1.73       8.67
  Glycoprotein (transmembrane) nmb                                                      Gpnmb         Dchil;ipd                        [NM_053110](NM_053110)       1.55       6.63
  Pleckstrin homology, Sec7 and coiled/coil domains 4                                   Pscd4         2510004M07Rik                    [NM_028195](NM_028195)       1.54       3.83
  B-cell leukaemia/lymphoma-2 related protein A1b                                       Bcl2a1b       A1-b                             [NM_007534](NM_007534)       2.49       6.35
  Complement component 1q, gamma                                                        C1qg          C1qc                             [NM_007574.1](NM_007574.1)   1.26       5.27
  Fc receptor, IgG, low affinity III                                                    Fcgr3         CD16                             [NM_010188.2](NM_010188.2)   2.10       5.84
  Lysozyme                                                                              Lyzs          Lys;Lzm;;Lzp                     [NM_017372.2](NM_017372.2)   5.80       21.72
  Chemokine (C-C motif) ligand 9                                                        Ccl9          CCF18;MRP-2;                     [NM_011338](NM_011338)       2.26       3.85
  B-cell leukemia 2 related protein A1d                                                 Bcl2a1d       A1-d                             [NM_007536](NM_007536)       2.51       4.49
  EGF-like module containing, mucin-like, hormone receptor-like 1                       Emr1          F4/80; Ly71;TM7LN3               [NM_010130.1](NM_010130.1)   1.54       3.44
                                                                                                                                                                               
  **Set 6 -- Day 16**                                                                   **Symobol**   **Synonyms**                     **Genebank ID**              **BMP4**   **Serum**
                                                                                                                                                                               
  Insulin-like growth factor 1                                                          Igf1          C730016P09Rik;Igf-1;Igf-I        [NM_010512.2](NM_010512.2)   1.6        4.8
                                                                                        Prss35                                         [NM_178738.1](NM_178738.1)   4.7        5.9
  Protein tyrosine phosphatase, non-receptor type substrate 1                           Ptpns1        CD172a; SHP-1;SHPS-1;            [XM_149178.1](XM_149178.1)   2.2        3.7
  Apolipoprotein A-II                                                                   Apoa2         Alp-2;Apoa-2;ApoA-II;Hdl-1       [NM_013474.1](NM_013474.1)   9.8        57.4
  Spondin 2, extracellular matrix protein                                               Spon2         ;M-spondin;Mindin                [NM_133903.2](NM_133903.2)   2.0        12.0
                                                                                                                                                                               
  **Set 7 -- Stem and late Day 16**                                                     **Symbol**    **Synonyms**                     **Genbank ID**               **BMP4**   **Serum**
                                                                                                                                                                               
  Fbox 15                                                                               Fbxo15                                                                      0.96       4.4
  Aurora kinase C                                                                       Aurkc         AIE1;AIK3;Stk13                  [NM_020572.1](NM_020572.1)   0.94       4.1
  2200001I15Rik                                                                                                                        [NM_183278.1](NM_183278.1)   0.94       6.4
  Hypothetical protein LOC236546                                                                      AF067061                         [NM_199060.1](NM_199060.1)   0.85       3.8
  Eukaryotic translation initiation factor 1A                                           LOC195150                                      [XM_111306.1](XM_111306.1)   0.80       9.3
  Similar to Pro-Pol-dUTPase polyprotein; RNaseH                                        LOC386244                                      [XM_359136.1](XM_359136.1)   0.88       5.2
  Similar to hypothetical protein FLJ35105                                              LOC245109                                      [XM_142517.3](XM_142517.3)   0.89       3.7
  Down regulated in renal cell carcinoma                                                Drr1          TU3A                             [AK044219](AK044219)         0.57       9.3
                                                                                                                                                                               
  **Set 8 -- Cardiac Day 16**                                                           **Symbol**    **Synonyms**                     **Genbank ID**               **BMP4**   **Serum**
                                                                                                                                                                               
  ATPase, Ca++ transporting, cardiac muscle, fast twitch 1                              Atp2a1        SERCA1                           [NM_007504.2](NM_007504.2)   6.9        1.1
  Cholinergic receptor, nicotinic, gamma                                                Chrng         Achr-3;Acrg                      [NM_009604.2](NM_009604.2)   4.5        1.0
  Myosin, light polypeptide 1                                                                                                          [BC059087.1](BC059087.1)     8.0        1.1
  Alpha actin, skeletal muscle                                                          Acta1         Acta-2;Acts;Actsk-1              [NM_009606.1](NM_009606.1)   25.3       1.2
  Tropomyosin 2 beta                                                                    Tpm2          Tpm-2;Trop-2                     [NM_009416.2](NM_009416.2)   11.6       1.3
  Cholinergic receptor, nicotinic, alpha                                                Chrna1        Achr-1;Acra                      [NM_007389.2](NM_007389.2)   4.1        1.0
  Troponin C2, fast                                                                     Tnnc2         Tncs                             [NM_009394.2](NM_009394.2)   5.7        0.9
  Neurofilament 3, medium                                                               Nef3          NF-M;NF160;Nfm                   [NM_008691.1](NM_008691.1)   4.5        1.1
  Myosin heavy chain                                                                    Myh8                                           [XM_354617](XM_354617)       6.7        1.1
  Cholinergic receptor, nicotinic, alpha 1                                              Chrna1        Achr-1;Acra                      [NM_007389.2](NM_007389.2)   5.4        1.1
                                                                                                                                                                               
  **Set 9 -- Cardiac 2 Day 6**                                                          **Symbol**    **Synonyms**                     **Genbank ID**               **BMP4**   **Serum**
                                                                                                                                                                               
  a-Actin, cardiac                                                                      Actc1         Actc-1                           [NM_009608.1](NM_009608.1)   31.2       3.6
  Somatostatin                                                                          Sst           Smst;SOM;SRIF;SS                 [NM_009215.1](NM_009215.1)   10.8       2.2
  Myosin, light polypeptide 7, regulatory                                               Myl7          MLC2a;MYL2A;;RLC-A               [NM_022879.1](NM_022879.1)   14.3       4.7
  Myosin, heavy polypeptide 7, cardiac muscle, beta                                     Myh7          Myhc-b;Myhcb                     [NM_080728.1](NM_080728.1)   8.2        2.4
  a-Actin, cardiac                                                                      Actc1         Actc-1                           [NM_009608.1](NM_009608.1)   26.3       3.5

![**QT clustering revealed sets of genes differentially expressed between serum and serum-free^B4L^EB culture**. QT clustering revealed nine sets of genes with similar dynamic expression profiles (Pearson Correlation coefficient of \> 0.9). In sets 1--7, expression is higher in serum (black sets). In sets 8--9, expression is greater in serum-free^B4L^EB culture (red sets). Some sets have been named based on the similarity of overall gene function during differentiation pathways (see Table 3).](1471-2164-8-365-4){#F4}

The genes in set 9 were expressed more highly in serum-free^B4L^media from day 6, and genes in set 8 showed up-regulation at day 12 and 16 in the absence of serum (Figure [4](#F4){ref-type="fig"}). Both sets are comprised almost exclusively of cardiac-specific genes such as myosin heavy chain 7 (*Myh7*), myosin light chain 7 (*Myl7*), the cardiac isoform of α-actin (*Actc1*), troponin (*Tnnc2*), tropomysin (*Tpm2*), the nicotinic cholinergic receptor (*Chrng*), and cardiac muscle fast twitch 1 specific ATPase (*Atp2a1*) (Table [3](#T3){ref-type="table"}). Further interrogation of the array data revealed a cohort of cardiac transcription factors, including ISL1, MEF2C, Bop/Smyd1 and Hand2 \[[@B39]\], which were transiently up regulated 1.4 to 3.5 fold in serum-free^B4L^media compared to serum at day 6 (Signet Login_Bruce). Importantly, this elevated cardiac gene expression program correlated with increased numbers of spontaneously beating EBs in serum-free^B4L^media (data not shown). Enhanced expression (\~100 fold) of *Actc1*, *Myl4*and *Myl7*in serum-free^B4L^media compared with serum-containing media was confirmed by qRT-PCR (Figure [1](#F1){ref-type="fig"}). Taken together, this data strongly suggests cardiac muscle cell differentiation is either inhibited in serum or enhanced by the addition of BMP4 to serum-free culture.

The genes in set 2 were expressed in both serum and serum-free^B4L^conditions immediately following primitive streak formation, but expressed to higher levels and slightly earlier in serum (Table [3](#T3){ref-type="table"} and Figure [4](#F4){ref-type="fig"}). Many of these genes are globins (both embryonic and definitive) suggesting erythropoiesis is activated more robustly in the presence of serum (See Discussion). *Alas2*, a gene encoding the erythroid specific isoform of the first and rate limiting enzyme in the heme biosynthesis pathway, and the erythroid specific transcription factor, p45-NF-E2 are also in set 2 \[[@B40]\]. qRT-PCR for α- and βh1-globin confirmed more rapid expression in serum versus SF^B4L^media (Figure [1](#F1){ref-type="fig"}), suggesting factors in addition to BMP4 enhance activation of the blood program from a similar primitive streak platform.

The genes in set 3 were expressed at a similar time in serum but expressed at very low levels or not at all in serum-free^B4L^media. Again, this set is highly enriched for erythroid specific genes such as alpha hemoglobin stabilising protein (*Ahsp*) \[[@B41]\], Glycophorin A, erythroid Kruppel-like factor (EKLF/*Klf1*) \[[@B42]\] and mitochondrial solute carrier protein (mitoferrin) \[[@B43]\] (Figure [4](#F4){ref-type="fig"} and Table [3](#T3){ref-type="table"}). Genes in sets 1 and 5 are activated more robustly at late time points in serum cultures. Most of these are specifically expressed in macrophages. Together, these results suggest delayed and less robust primitive haematopoiesis occurs in SF^B4L^culture compared with serum, an observation confirmed by less robust erythroid cell generation and \'redness\' of the EBs from day 6--10 of differentiation (data not shown).

Rapid changes in Kruppel-like factor gene expression upon ES cell differentiation
---------------------------------------------------------------------------------

Three Kruppel-like factor genes, *Klf2*, *Klf4*and *Klf5*, were rapidly down regulated during the first few days of EB development (bold type in Table [1](#T1){ref-type="table"}). All are members of the KLF family of transcription factors which are characterized by a similar C-terminal domain of three C~2~H~2~zinc fingers which confers binding to CACC box elements in promoters and more distant regulatory elements \[[@B44],[@B45]\]. *Klf2*and *Klf4*have N-terminal transcriptional action domains and act primarily as transcriptional activators, whereas *Klf5*is best known as a transcriptional repressor \[[@B46]\]. Until recently, *Klf2*and *Klf4*were considered to have restricted expression patterns \[[@B47],[@B48]\] with gene knockout animals showing late developmental defects in vasculogenesis and skin differentiation, respectively \[[@B49],[@B50]\]. Recently however, *Klf4*expression was noted in ES cells \[[@B19],[@B51]\], and forced expression was shown to enhance Oct4 expression and promote self-renewal \[[@B51]\].

qRT-PCR confirmed the rapid down regulation of *Klf*2, *Klf4*and *Klf5*in both serum and serum-free^B4L^differentiation conditions, although *Klf5*expression was down regulated more slowly (Figure [5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}, and Table [4](#T4){ref-type="table"}). *Klf2*, *Klf4*and *Klf5*were all re-induced from day 3--5 of differentiation as mesoderm and endoderm developmental pathways are activated (Figure [5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}). Sixteen of the 17 known KLFs were examined in detail throughout the entire differentiation time course (Table [4](#T4){ref-type="table"}). *Klf9*was also steadily down regulated (\>10 fold) between ES cells and day 5 EBs in serum and serum-free^B4L^media (Figure [5B](#F5){ref-type="fig"}). *Klf3*, a well characterized transcriptional repressor \[[@B52]\] via its ability to recruit the co-repressor, CtBP \[[@B53]\], displayed an interesting biphasic expression pattern with initial rapid down regulation then re-induction from days 5--6 (Figure [5B](#F5){ref-type="fig"}). In contrast, *Klf16*displayed little change in expression levels over the 16 days of EB maturation (Figure [5B](#F5){ref-type="fig"}).

###### 

Kruppel-like factor gene expression during ES cell differentiation

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  **Symbol**   **Synonyms**               **Genbank ID**            **Illumina^®^Probe ID**   **Absolute Expression Level**                        
  ------------ -------------------------- ------------------------- ------------------------- ------------------------------- ------ ------ ------ ----------
  Klf1         Eklf                       [NM_010635](NM_010635)    scl33570.4.1_25-S         110                             105    125    114    **2138**

  Klf2^a^      Lklf                       [NM_008452](NM_008452)    scl016598.3_26-S          **2275**                        269    157    272    248

  Klf3^b^      Bklf;Tef-2                 [AK046659](AK046659)\     ri\|B430304G02\| 3393-S   112                             92     80     102    99
                                          [NM_008453](NM_008453)                                                                                   

                                                                    scl0016599.2_295-S        894                             406    733    374    881

                                                                    scl27779.8_253-S          638                             182    422    251    442

  Klf4^a^      Gklf; Zie                  [NM_010637](NM_010637)    scl0016600.2_155-S        149                             85     86     104    102

                                                                    scl0016600.2_249-S        **575**                         89     109    112    127

                                                                    scl016600.7_29-S          101                             69     64     86     83

  Klf5^a^      Bteb2;IKLF                 [NM_009769](NM_009769)    scl0012224.2_233-S        **1981**                        699    232    699    274

                                                                    scl45215.1.1_294-S        79                              91     83     112    105

                                                                    scl46026.3_338-S          183                             91     78     112    99

  Klf6         BCD1;CPBP;Klf6;Zf9         [NM_011803](NM_011803)    scl023849.4_8-S           1107                            1697   1540   1996   1457

                                                                    scl45096.3_115-S          177                             251    221    307    232

  Klf7         9830124P08Rik              [AK086122](AK086122);\    ri\|D930007C01\| 2481-S   319                             243    207    270    227
                                          [NM_033563](NM_033563)                                                                                   

                                                                    scl0093691.2_69-S         334                             281    202    345    231

                                                                    scl16685.5_486-S          439                             398    305    440    309

  Klf8         Klf8                       [NM_173780](NM_173780)    scl0245671.1_6-S          136                             113    116    139    120

  Klf9^a^      BTEB-1;Klf9                [NM_010638](NM_010638)    scl53274.2_128-S          **2035**                        910    205    1120   394

  Klf10        Tieg1; Egra; Tieg          [NM_013692](NM_013692)\   scl47275.9_20-S           84                              83     70     96     92
                                          [AK043433](AK043433)                                                                                     

                                                                    ri\|A730095A08\| 2144-S   71                              65     64     93     81

  Klf11        Tieg3; Tieg2b; FKLF        [NM_178357](NM_178357)    scl0194655.4_70-S         71                              68     67     86     78

  Klf12        AP-2rep;B130052C06Rik      [NM_010636](NM_010636)    scl000297.1_3-S           75                              70     70     104    93

                                                                    scl0016597.1_0-S          79                              81     70     104    93

                                                                    scl016597.1_75-S          92                              102    86     122    121

                                                                    scl45206.9.1_30-S         79                              81     85     101    92

                                                                    scl45212.1.365_19-S       62                              61     56     75     73

  Klf13        Bteb3;FKLF2; RFLAT-1       [NM_021366](NM_021366)    scl31250.6.4_21-S         291                             284    245    332    308

  Klf14        1110025J03Rik;Epfn;Klf14   [NM_031183](NM_031183)    scl0083395.1_307-S        109                             141    103    168    140

                                                                    scl13960.1.1_83-S         167                             193    166    237    183

                                                                    scl13961.1.1_105-S        83                              75     73     104    87

  Klf15        1810013I09Rik;CKLF;KKLF    [NM_023184](NM_023184)    scl29751.3_94-S           118                             125    101    156    120

  Klf16^a^     BTEB4;DRRF                 [NM_078477](NM_078477)    scl37728.2_209-S          **355**                         181    177    249    167
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

a\. Enriched in undifferentiated ES cells

b\. Biphasic expression pattern (See Figure 5)

![**Kruppel like factors (Klfs) are dynamically expressed during the first few days of ES cell differentiation**. (**A**) GeneSpring plot of normalized gene expression for all KLFs detected during ES cell differentiation in serum or serum-free^B4L^culture. Most of the genes are listed on the y-axis in order from their highest relative expression in ES cells. There is dramatic up regulation of *Klf1 (Eklf)*only in serum following day 6 of differentiation. Plots representing *Nanog*(red), *Sox2*(red) and *Pou5f1(Oct4)*(green) are shown for comparison. *Pou5f1*and *Nanog*gene expression persists at high levels for 2--3 days after *Klf2*, *Klf4*and *Klf5*are down regulated. (**B**) Validation of changes in gene expression of six members of the KLF family by quantitative real time RT-PCR. Scheme as described for Figure 2B.](1471-2164-8-365-5){#F5}

*Klf2*and *Klf4*co-localize with *OCT4*in the nuclei of ES cells (Figure [6A](#F6){ref-type="fig"}). Interestingly, all three proteins were found to preferentially reside in a nuclear sub-compartment (possibly nucleoli for transcription factories), suggesting possible co-involvement in a protein complex or network. Also, endogenous KLF2 was detected by specific CACC box DNA-binding activity in undifferentiated ES cells, which was lost upon EB differentiation (Figure [6B](#F6){ref-type="fig"}). In contrast, endogenous ES cell KLF4 DNA binding activity was not detected using the p18INK4c promoter CACC box sequence, although recombinant KLF4 was shown to bind to this probe (data not shown). SP1 and SP3 are ubiquitously expressed CACC-box binding proteins, which are dominant in ES cell nuclear extracts (Figure [6B](#F6){ref-type="fig"}). We hypothesize KLF2, KLF3, KLF4, KLF5 and KLF6 compete with SP1 family members for DNA binding to key *cis*elements in various stem cell genes to regulate expression in positive and negative fashions (see Discussion).

![**Kruppel like factor expression and DNA binding activity during ES cell differentiation**. (**A**) Co-expression of Oct4 with KLF2 or KLF4 in ES cells. Indirect immuno-fluorescence shows co-localization of KLF2 and KLF4 with Oct4 in sub-nuclear compartments (possibly nucleoli). Individual confocal images for OCT4, KLF2, KLF4, and DAPI are shown with the corresponding composite image. Scale bar 40 μm. (**B**) Electro-mobility gel shift assay showing changes in DNA binding activities at a conserved CACC box site in the p18-INK4c gene promoter. Nuclear extracts were generated from ES cells or EBs differentiated for four days in serum. Super-shifts were performed with specific antisera for SP1, SP3, KLF2, KLF3, and KLF4 (See Methods). There is strong binding of endogenous Sp1 to the CACC element in ES cells and EB cells. KLF2 DNA-binding activity is present in ES cells as determined by a specific inhibition of binding of the indicated DNA complex with a KLF2 antibody. This activity is lost upon differentiation into EBs. The identity of the CACC box binding activity in EBs denoted CAC-X, and the binding activity in ES cells denoted CAC-Y, was not definitively identified using this panel of antibodies.](1471-2164-8-365-6){#F6}

Enrichment of KLF-binding cis elements in the proximal promoters of stem cell specific genes
--------------------------------------------------------------------------------------------

To investigate whether Kruppel-like factors might directly regulate stem cell gene expression, and therefore play a role in the maintenance or loss of \'stemness\', the presence of KLF transcription factor binding sites (TFBS) within the proximal promoters of all genes in Table [1](#T1){ref-type="table"} was determined. Although a position weighted matrix (PWM) for KLF4 binding site specificity has been published \[[@B54]\], this site does not resemble the CACC box sequences known to bind other KLFs. Since KLF4 has identical DNA-binding residues in each of its three C-terminal C~2~H~2~zinc fingers to other members of the Kruppel-like factor family \[[@B45]\], it should bind to similar sequences. Based on the crystal structure of the zinc fingers of Zif268 and SP1 bound to DNA \[[@B55],[@B56]\], and testing of specific binding of CACC box variants to recombinant KLF1, KLF3 and KLF17 \[[@B45],[@B52],[@B57],[@B58]\], a generic KLF TFBS has been proposed. Although a SELEX experiment for KLF1 binding has not been published, experiments from our group suggest a C at position 1, an A or C at position 3, an A at position 5, and an A, T or C at position 9 of the 9 bp consensus provides enhanced affinity for KLF1 binding. Taken together, these studies have enabled the development of a PWM (called here KLF-A) that should predict KLF4, KLF2 and other KLF TFBSs (see Methods and Additional file [7](#S7){ref-type="supplementary-material"}).

Clover \[[@B59]\] was used to determine if defined TFBSs were statistically over-represented in the stem cell lists. We searched for PWMs for KLF-A, KLF4 \[[@B54]\], octamer, extended octamer, nanog, and Oct-Sox binary sites as well as negative control sites (gata-1 and E-box) in sequences 2 kb upstream of the TSSs of stem cell genes (Table [1](#T1){ref-type="table"}), versus 2 kb of sequences upstream of the entire murine transcriptome (See Additional file [7](#S7){ref-type="supplementary-material"} for details of PWMs). There was significant over-representation of KLF-A TFBS within the first 2 kb of promoter sequences from the stem list gene list (p value of \< 0.01) (Figure [7A](#F7){ref-type="fig"}), as well as over-representation of octamer sites and extended Oct4-binding sites as defined from ChIP-PET data \[[@B60]\]. No statistically significant over-representation of KLF4 \[[@B54]\], NANOG, GATA1 or E-box TFBSs were identified. All genes in the rapidly down regulated gene list have at least one KLF-A type CACC site, or octamer or Oct4 \[[@B60]\] TFBS. A full list of the promoters with highlighted sites is available on request. Together, this data strongly suggests direct transcriptional regulation of many stem cell genes by KLFs.

![**KLF and octamer binding sites are highly enriched in stem cell gene promoters**. (**A**) A Clover analysis was used to identify over-represented transcription factor binding sites within the promoter sequences of all stem cell genes identified in Table 1. Representative gene promoters are shown, indicating KLF-A binding sites (pink), octamer sites (ATGCWAAT) (green) and extended Oct4 binding sites (Oct4-Loh)(cyan) \[60\]. (**B**) Clover output for 2 kb of promoter sequence of murine *Zfp42*/*Rex1*. The positions and sequences corresponding to PWMs for KLF-A, octamer and Oct4 occupancy sites are indicated in the table and colour coded in the sequence. The positions are relative to the transcriptional start site. (**C**) ECR Browser output of conserved sequence identity between mouse and rat in the promoter and part of the first intron of the *Zfp42*gene. The blue arrows indicate the direction of transcription. Yellow indicates the extent of the first (non-coding) exon, pink indicates regions of sequence conservation in the first intron and red indicates regions of sequence conservation in the 5\' upstream region. rVISTA was used to find all of the KLF-A and octamer sites in the murine gene (Murine only) and conserved sites between mouse and rat (Conserved mouse, rat).](1471-2164-8-365-7){#F7}

The *Zfp42*/*Rex1*gene promoter is presented as an example of output from the Clover program (Figure [7B](#F7){ref-type="fig"}). It contains five KLF-A, one octamer and three OCT4 TFBS. The two CACC box elements within the first 250 base pairs of the TSS represent classical extended KLF-binding sites \[[@B42],[@B61]\]. These regions are the same as previously reported \[[@B62]\] although their functional importance has not been determined. Interestingly, two of the three KLF-A TFBS were evolutionarily conserved between the mouse and rat gene promoters (Figure [7C](#F7){ref-type="fig"}). Also, two further conserved CACC sites at -1.4 and -1.5 kb were identified within 500 bp of extended evolutionary conservation (\>70% identity) (Figure [7C](#F7){ref-type="fig"}). This might act as a KLF dependent enhancer. Most of the stem cell genes in list 1 have conserved CACC box elements in their promoters \[[@B63]-[@B66]\]. In some cases these have been reported to bind the ubiquitous SP1, but our Clover analysis suggests they are also likely to bind KLFs (see Discussion).

Discussion
==========

Expression profiling of murine ES cell differentiation was undertaken over a 16-day time course. We compared gene expression in methylcellulose cultures containing serum versus chemically defined media containing LIF (1 U/ml) and low concentrations of BMP4 (2 ng/ml) \[[@B67]\]. The Illumina^®^Sentrix Mouse 6 bead array provided a sensitive and detailed platform for analysis of dynamic gene expression. Using various data mining approaches, lists of stem cell-enriched genes and genes that are induced during the *in vitro*equivalent of epiblast and primitive streak stages of differentiation were generated. In combination with other ES cell profiling studies \[[@B7]\], our detailed expression data provides a useful resource for future reverse genetic approaches (i.e. siRNA knockdown) to study the function of these genes during ES cell differentiation and *in vivo*development. We also found a number of previously uncharacterized cDNAs (RIKEN clones) which could play important roles during development.

Importantly, the loss of pluripotency, measured by Oct4 gene expression, was comparable between serum and serum-free^B4L^EB culture, following a predicted decrease over the first 6 days. Surprisingly, Oct4 gene expression gradually increased following day 6, an observation independent of the cell lines used (data not shown). It remains undetermined if expansion of Oct4 positive ES cells persists as undifferentiated populations within our EB culture system. Previous studies have identified the development of Oct4 positive primordial germ cells (PGC) following 12 days of ES cell differentiation \[[@B68]-[@B70]\], suggesting the Oct4 profile may alternatively represent the expansion of non-ES cell populations. Although the expansion of some undifferentiated ES cells is possible, the array profile does not suggest global persistence or up-regulation of ES gene expression late in the EB program. Also, markers of mesoderm induction such as brachyury and Mixl, do not show persistent up-regulation following peak expression at day 4, suggesting EBs are unlikely to harbour cells which are delayed or arrested from entering the differentiation program.

We found significant differences in cardiac gene expression during EB differentiation in serum and serum-free^B4L^culture. Our current understanding of cardiac development provides possible insights into this observation. Briefly, *in vivo*studies have revealed BMPs secreted from the anterior lateral plate, and ill-defined signals from anterior primitive endoderm, are key inducers of cardiac development \[[@B71]-[@B73]\]. The administration of recombinant BMP2 or BMP4 to chick explant cultures induces cardiac differentiation in non-cardiogenic mesoderm \[[@B71]\] and *Bmp2*knockout animals develop cardiac abnormalities \[[@B74]\]. Conversely, Wnts secreted by the neural tube are strong suppressors of cardiogenesis. Together, these opposing signals act to establish the borders of the heart field \[[@B71],[@B75]\]. By mimicking the environment that establishes cardiogenesis *in vivo*, assays capable of directing cardiomyocyte production from ES cells have been established. BMPs can efficiently enhance the cardiac program when added to EB culture \[[@B76],[@B77]\], whereas BMP inhibition drastically suppresses this outcome. In our hands cultures supplemented with BMP4 (2 ng/ml) supported cardiomyocyte maturation (as determined by expression of cardiac specific genes) with greatest expression detected at Day 8--10. This correlated with increased numbers of spontaneously beating EBs, and the timing of initial spontaneous contractions during murine embryogenesis \[[@B78]\]. The cardiac program was significantly reduced in culture containing 10% serum, an observation supported by a number of other studies \[[@B79],[@B80]\]. This suggests the constituents of serum are inhibitory to cardiomyocyte development. Although a detailed assessment of cardiomyocyte differentiation was not the focus of this analysis, the array output, qRT-PCR profiles and morphological observations described supports the usefulness of this assay in future investigations. In addition, the defined constituents of serum-free^B4L^media provides an excellent opportunity to identify additional recombinant factors required to further expand cardiac progenitor cell production from EBs.

In contrast, the hematopoietic program was more pronounced within EBs grown in 10% serum than BMP4 alone (Figure [1](#F1){ref-type="fig"} and [4](#F4){ref-type="fig"}). In particular, EKLF (*Klf1*) expression was significantly reduced in serum-free media supplemented with BMP4 (2 ng/ml) compared with serum (Figure [5A](#F5){ref-type="fig"} and Table [4](#T4){ref-type="table"}). EKLF is essential for regulation of a large cohort of erythroid specific genes \[[@B81],[@B82]\], many of which were identified in sets 2 and 3 (Figure [4](#F4){ref-type="fig"}). Thus, it is likely that reduced EKLF expression in SF^B4L^media directly results in inhibition of a cascade of erythroid gene expression. Previous work showed the addition of BMP (at 5 ng/ml) to serum-free ES cell culture induces EKLF expression and restores hematopoietic cell differentiation \[[@B83]\]. Although a weak hematopoietic program was observed in SF^B4L^culture, the concentration of BMP4 used was less than that used by Adelman et al. Thus, we suggest a robust cardiac (anterior-ventral mesoderm) gene expression program is induced by low conentrations of BMP4 (or other BMPs), whereas a robust blood gene expression program (posterior-ventral mesoderm) requires \>2 ng/ml of BMP4 or additional growth factors. Recently, mesoderm derived progenitor cell populations for hematopoietic and cardiac lineages were studied during EB development using ES cells in which GFP is targeted to the brachyury locus \[[@B80]\]. Within day 3.25 EBs, GFP^+^Flk1^+^cells were shown to represent hematopoietic precursors, whereas GFP^+^Flk1^-^cells were significantly enriched for cardiac progenitor populations. It would be interesting to determine if the ratio of Flk1^+^/Flk1^-^within the brachyury positive population is altered between our two culture conditions.

A number of the Kruppel-like factor family of transcription factors were dynamically expressed in the first few days of ES cell differentiation. It was initially surprising to find highly enriched *Klf2*and *Klf4*expression in ES cells, since both are considered markers of terminally differentiated cell types such as skin \[[@B50]\], gut \[[@B84]\], vascular smooth muscle \[[@B49],[@B85]\] and lymphocytes \[[@B86]\]. However, recent evidence suggests KLFs may regulate stem cell function, since *Klf4*is enriched in ES cells \[[@B19]\] and forced over-expression within these cells can maintain pluripotency in the absence of LIF \[[@B51]\]. Furthermore, *Klf4*can bind the Lefty1 gene core promoter co-operatively with *Oct4*and *Sox2*\[[@B65]\]. Although Lefty 1 and 2 are best characterized as repressors of nodal, acting to regulate left-right patterning \[[@B87]\], our results and those of others, suggest a possible redundant role for lefty proteins during the maintenance of ES cell pluripotency \[[@B65]\]. Similarly to the Oct4 expression profile, many of the KLF family members also increased in expression late in the differentiation program. As mentioned, the KLFs are expressed in diverse tissues during development. It is therefore expected that the profiles obtained reflect the generation and early specification of mesoderm and endoderm cells following primitive streak gene activation at day 4.

Based on the likely identical binding specificity of the KLF family, established transcriptional activation and repression roles of certain family members \[[@B44]\], and bioinformatic evidence of a high prevalence of KLF TFBSs in many stem cell genes, we propose KLF competition for occupancy of these CACC box elements might determine self-renewal versus differentiation of ES cells. According to this model, high levels of KLF2 and KLF4 expression in undifferentiated ES cells would lead to occupancy of CACC box elements in promoters of stem cell genes such as *Pou5f1/Oct4*, *Nanog, Esrrb, Zfp42/Rex1, Lefty1*and *Lefty2*. Furthermore, the *Klf2*and *Klf4*genes themselves have CACC box elements in their proximal promoters (Figure [7A](#F7){ref-type="fig"}), suggesting a positive feedback loop within ES cells is likely. Interestingly, gene knockout and lentiviral shRNA gene knockdown of *Klf2*or *Klf4*, does not lead to an obvious stem cell defect \[[@B19],[@B49],[@B50],[@B85]\], suggesting these two KLFs may have functionally redundant roles during the maintenance of pluripotency. Future analysis of KLF2/KLF4 double knockout ES lines or the knockdown of both proteins using RNAi technologies will be necessary to validate this hypothesis. Upon ES cell differentiation, down regulation of *Klf2*and *Klf4*was very rapid, whereas down regulation of *Oct4*and *Nanog*was delayed for one to two days. We suggest loss of KLF2 and KLF4 binding to *Pouf1/Oct4*, *Nanog*, *Esrrb*and perhaps other stem cell promoters, could be directly responsible for their down regulation. Moreover, *Klf5*was down regulated more slowly, and *Klf3*was up-regulated in the first two days of differentiation, suggesting these KLFs may function primarily as transcriptional repressors at the *Pouf1*/*Oct4*, *nanog, Zfp42*and *Esrrb*gene promoters. Once this differentiation driving transcription network is activated we suggest KLF3, KLF5 and KLF9 can accelerate loss of the stem cell state by directly repressing expression of the *Klf2*and *Klf4*genes themselves. Therefore, a combination of cross regulation of transcriptional outputs, and competition for occupancy of key stem cell promoters by KLF proteins with differing biochemical properties but identical DNA-binding capacities, may determine self-renewal versus differentiation outcomes. Again validation of this model requires functional analysis. It is important to note we have not proven occupancy of stem cell gene promoters by the KLFs *in vivo*. Chromatin immuno-precipitation (ChIP) experiments in ES cells and differentiated populations are essential to validate this model, however ChiP grade antibodies are not currently available.

This scenario is not necessarily limited to ES cell differentiation. A similar program may take place in many adult stem and progenitor cells populations. Certainly competition between *Klf4*and *Klf5*has been suggested to regulate cell growth \[[@B88]\], and *Klf1*and *Klf3*compete for binding and have opposing effects in blood cells \[[@B89]\]. Furthermore, an imbalance between occupancy of key stem cell or proliferation gene promoters by KLFs, with differing activating and repressing functions, could be responsible for the development or progression of many common forms of cancer. For example, loss of hetero-zygosity for *Klf4*and *Klf5*has been found in colon, stomach, breast, prostate and liver cancers \[[@B90],[@B91]\].

In addition to the proposed complex transcriptional interplay between KLFs and stem cell gene promoters, direct protein-protein interactions and protein networks involving KLFs are possible. We showed sub-nuclear localization of KLF2 and KLF4 with OCT4 in ES cells (Figure [6A](#F6){ref-type="fig"}), and KLF4 can co-operate with OCT4 and SOX2 to drive expression of the Lefty1 core promoter \[[@B65]\]. Also, very recent biochemical purification of NANOG-interacting proteins discovered KLF4 as part of a NANOG-OCT4 network in ES cells (Stuart Orkin, personal communication). This is also consistent with the ability of KLF4 to co-operate with OCT4, SOX2 and c-MYC to drive de-differentiation of fibroblasts into ES-like cells \[[@B24]\].

Conclusion
==========

Defining the genetic regulation of ES cell self renewal and differentiation will be instrumental for the development of future cell based therapies. Using 47 K Illumina^®^Sentrix bead arrays, the differential expression of genes during 16 days of ES cell differentiation was determined. Hierarchical gene clustering and correlation statistical analyses lead to the identification of a small cohort of genes which define the stem cell state. Historically, ES cell differentiation is achieved in culture media containing 10--15% FBS. A direct comparison between ES cell differentiation in serum and a serum-free media was undertaken. Surprisingly, global gene expression profiles were comparable between culture conditions, with the exception of mesoderm derived cardiac and haematopoietic transcripts. These results support the use of defined serum-free approaches for the directed differentiation of ES cell commitment. Expression of many KLF family members were enriched in ES cells and rapidly down regulated upon differentiation. KLF2 and KLF4 were co-localisation with OCT4 in ES cell nuclei and KLF transcription factor binding sites were over-represented within the promoters of the putative ES cell gene list (p \< 0.01). Taken together, this data strongly suggests KLF family members regulate the maintenance of ES cell pluripotency.

Methods
=======

ES cell culture, embryoid body formation and immunohistochemistry
-----------------------------------------------------------------

W9.5 ES cell differentiation was performed as described (Bruce et al., Differentiation, in press). For immuno-fluorescence, feeder depleted W9.5 ES cells were seeded onto sterile gelatin-coated glass cover slips in ES cell media, fixed in 4% PFA for 10 min then washed in PBS. Cover slips were boiled in 10 mM citric acid (pH 6.4) for 10 min, washed in PBS and permeabilized in 0.18% triton X-100 in PBS for 10 mins. For OCT4/KLF4 detection, the cover slips were blocked in 1% BSA then incubated with rabbit polyclonal antibody raised against OCT4 (Abcam \#ab19857) and goat Anti-mouse KLF4 (R&D Systems \#AF3158) overnight at 4°C, then incubated in goat anti-rabbit Alexa-488 (1:400) (Molecular Probes \#A11008) and donkey anti-goat Alexa-647 (1:400) for 1 hour. For co-detection of OCT4/KLF2, the Zenon Rabbit IgG labelling kit was used (Molecular Probes \#Z-25308). 1 μg of KLF2 rabbit polyclonal antibody (Santa Cruz SC-28675) was labeled with Alexa647 Fab fragment following the manufacturer\'s instructions. Cover slips already stained for OCT4 (Alexa488) were incubated with labeled KLF2 for 1 hr then washed and post-fixed in 4% PFA to ensure strong signal detection. DAPI 1:5000 (Molecular Probes \#D3571) was used to detect nuclear localization. Cover slips were mounted on SuperFrost^®^Plus slides (Menzel-Glaser) with VectaShield mounting media (Vector Laboratories H-1000). Confocal microscopy was performed on LSM 510 META Carl Zeiss microscope system.

RNA extraction, cDNA synthesis and real-time RT-PCR data analysis
-----------------------------------------------------------------

Total RNA was made using TRIzol (Invitrogen), and cDNA was synthesized from 2 μg of DNase1-treated total RNA using Superscript III (Invitrogen) and oligo-DT~12--15~(Promega) according to the manufacturer\'s instructions. Quantitative RT-PCR (qRT-PCR) was carried out using the Applied Biosystems SYBR-green dye system and 7500 Real Time Cycler in 96-well plates. Cycling variables were as follows: 50°C for 2 minutes, 95°C for 10 minutes, then 40 cycles of 15-second denaturation at 95°C and 1-minute at appropriate annealing temperatures, optimized for each set of primers based on dissociation curves (Additional file [8](#S8){ref-type="supplementary-material"}). Expression levels were normalized to HPRT as determined from the ratio of delta CT values. Mean of relative expression ± SD was determined from three biological replicates. Sequencing of gel-purified amplicons was performed to ensure correct product amplification.

Micro-array hybridization and analysis
--------------------------------------

Expression profiling was performed using Sentrix Mouse-6 Expression BeadChip arrays from Illumina^®^. RNA was assessed for integrity using the Agilent Bioanalyzer 2100 and RNA integrity (RIN) scores above 9.5 were present in all samples. Amplification was performed with 500 ng of total RNA using the Illumina TotalPrep RNA Amplification kit (Ambion) with a 12 hour in vitro transcription reaction period. The quantity and quality of biotin-UTP incorporated cRNA was also assessed on the Agilent Bioanalyzer 2100. Amplified cRNA (1500 ng per array) was hybridized to Mouse-6.v1 BeadChip arrays according to the manufacturer guidelines and detected with Fluorolink Streptavidin-Cy3 (Amersham Biosciences). Arrays were scanned using the Illumina BeadStation Scanner. The raw intensity values obtained for the scanned array images were compiled using the proprietary BeadStudio v1.5.1.3 software and imported into GeneSpring GX v7.3.1 (Agilent). A mouse Illumina probe set was defined in the GeneSpring Workgroup using the Illumina targetIDs as the unique identifiers and annotated according to array content files supplied by illumina^®^. Data normalization was performed by first setting all measurements less than 0.01 to 0.01, then applying per chip normalization to the 50^th^percentile, and per gene normalization to the median.

From an interpretation which included the three FBS experiments, a non-parametric Welch ANOVA (where variances were not assumed equal) was performed on all 46,120 probes to find a subset of genes whose expression varied significantly throughout the differentiation time course. A Benjamini and Hochberg False Discovery Rate multiple testing correction was applied to reduce the number of false positives. This yielded a set of 7,967 probes that showed statistically significant (p \< 0.05) differences in expression by Welch t-test. This approach simplified running the data mining algorithms to find syn-expression patterns by removing genes such as housekeeping genes which did not display differential expression, or genes which did not reach a threshold of expression at any time points.

Genome interpretations were generated in GeneSpring GXv7.3.1 (Agilent) in which the mean relative expression level for each gene was represented at each time point relative to the average of all time points. A number of statistical approaches were used to find syn-expression patterns. A Pearson correlation (between 0.9 and 1.0) was performed to find genes with similar expression profiles to *Pouf1/Oct4*, *nanog*, *sox2*, *fgf5*, *wnt5*and *brachyury*. Hierarchical clustering was performed using the gene by gene and group by group \'tree\' algorithm within the GeneSpring (Agilent) program. This compares each probe with every other in the lists to generate similarity statistics and a tree representation of similarity based on a Pearson correlation. Also, quality threshold (QT) clustering \[[@B92]\] was used to define distinct subsets of co-expressed genes. The entire data set for the experiments is available via GEO as well as via our instance of Genespring (contact corresponding author).

Electro-mobility gel shift assays (EMSA)
----------------------------------------

Nuclear extracts were made from undifferentiated ES cells and embryoid bodies grown for four days in 10% serum. Electromobility gel shift assays (EMSA) were performed as previously described \[[@B61]\] using double stranded oligonucleotide probes corresponding to an extended CACC site in the p18INK4c promoter (sense strand 5\'-gttgggcggggcgtgggcggggcc-3\') (Tallack, et al., submitted). Supershifts were performed with specific antibodies raised against SP1 (Santa Cruz SC-059x), SP3 (Santa Cruz SC-644x), KLF2 (Santa Cruz SC-28675), KLF3 \[[@B52]\] and KLF4 (Santa Cruz SC-12538x).

Bioinformatic searches for CACC sites and other over represented elements in promoters of stem cell genes
---------------------------------------------------------------------------------------------------------

The data-mining tool Biomart (accessed via Ensembl release 36 of the mouse genome), was used to collate 2 kb of sequences upstream of the transcriptional start sites (TSSs) of all genes listed in Table [1](#T1){ref-type="table"}. The Clover program, run via the MotifViz web interface \[[@B59]\], was used to search for over-representation of position weighted matrices (PWMs) for octamer \[[@B93]\], Oct4 \[[@B60]\], Oct-Sox \[[@B60]\], KLF4 \[[@B54]\], E-box, GATA-1 \[[@B94]\] and CACC (KLF-A) elements in these promoter sets. The PWMs are listed in Additional file [7](#S7){ref-type="supplementary-material"}. The ECR Browser \[[@B95]\] was used to determine phylogenetic conservation of cis elements between mouse, rat and human genomes.
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